(Q46168942)

20 December 2017

title

gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis (English)

1 reference

20 December 2017

Mycobacterium tuberculosis

main subject

0 references

1 reference

1 reference

2

1 reference

20 December 2017

Elizabeth Streicher

3

1 reference

20 December 2017

Paul van Helden

5

object named as

Paul D van Helden

1 reference

20 December 2017

author name string

Frederick A Sirgel

1

1 reference

20 December 2017

Thomas C Victor

4

1 reference

20 December 2017

Erik C Böttger

6

1 reference

20 December 2017

language of work or name

English

0 references

publication date

22 February 2012

1 reference

20 December 2017

Journal of Antimicrobial Chemotherapy

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

20 December 2017

volume

67

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

page(s)

1088-1093

1 reference

20 December 2017

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Fluoroquinolones, tuberculosis, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Spoligotype signatures in the Mycobacterium tuberculosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Mycobacterium tuberculosis Beijing genotype: a template for success.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Clonal expansion of a globally disseminated lineage of Mycobacterium tuberculosis with low IS6110 copy numbers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

The ins and outs of Mycobacterium tuberculosis drug susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS033

21 January 2018

Identifiers

DOI

10.1093/JAC/DKS033

1 reference

20 December 2017

PubMed ID

22357804

1 reference

20 December 2017